JP2013513612A5 - - Google Patents

Info

Publication number

JP2013513612A5

JP2013513612A5 JP2012543284A JP2012543284A JP2013513612A5 JP 2013513612 A5 JP2013513612 A5 JP 2013513612A5 JP 2012543284 A JP2012543284 A JP 2012543284A JP 2012543284 A JP2012543284 A JP 2012543284A JP 2013513612 A5 JP2013513612 A5 JP 2013513612A5

Authority

JP

Japan

Prior art keywords

compound

composition

item

composition according

pharmaceutically acceptable

Prior art date

2010-12-09

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims description 29
• PVPBHKCSQBLDEW-ZQOBQRRWSA-N (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol 4-hydroxybutane-1-sulfonic acid Chemical compound OCCCCS(O)(=O)=O.OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O PVPBHKCSQBLDEW-ZQOBQRRWSA-N 0.000 claims description 16
• 150000003839 salts Chemical class 0.000 claims description 12
• 150000002634 lipophilic molecules Chemical class 0.000 claims description 11
• 208000002780 macular degeneration Diseases 0.000 claims description 11
• 229910052708 sodium Inorganic materials 0.000 claims description 11
• 239000011734 sodium Substances 0.000 claims description 11
• 230000000699 topical effect Effects 0.000 claims description 9
• 229940126062 Compound A Drugs 0.000 claims description 8
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 8
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 7
• 229910019142 PO4 Inorganic materials 0.000 claims description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
• 239000007864 aqueous solution Substances 0.000 claims description 4
• 150000001875 compounds Chemical class 0.000 claims description 4
• 239000010452 phosphate Substances 0.000 claims description 4
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 4
• LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 4
• 239000000243 solution Substances 0.000 claims description 4
• 208000027073 Stargardt disease Diseases 0.000 claims description 3
• 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 3
• 208000008069 Geographic Atrophy Diseases 0.000 claims description 2
• 238000000034 method Methods 0.000 description 14
• 238000009472 formulation Methods 0.000 description 3
• 239000002243 precursor Substances 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1